Différences

Ci-dessous, les différences entre deux révisions de la page.

--- start [2023/01/17 18:10]
remyfroissart [Collective scientific responsabilities]
+++ start [2025/04/10 10:15] (Version actuelle)
remyfroissart [Research interest]
@@ Ligne 28: / Ligne 28: @@
 In 2014, I decided to come back on phage'evolution through a collaboration with [[ http://www.idm.uct.ac.za/Jo-Ann_Passmore|Jo-Ann Passmore]] (University of Cape-Town, South-Africa), [[ https://virostyle.cnrs.fr/team/ignacio-bravo/|Ignacio Bravo]] (MIVEGEC, Montpellier, France) and [[ https://marievasse.eu/|Marie Vasse]] (post-doc, MIVEGEC, Marie-Curie grant) with whom we are working on disturbance of microbial vaginal ecosystem that may results on dysbiosis (in particular, bacterial vaginosis).
-I also work with [[ https://isem-evolution.fr/membre/martin/|Guillaume Martin]] (CNRS, ISEM, Montpellier, France) and [[ https://www.researchgate.net/profile/Yoann-Anciaux|Yoann Anciaux]] (post-doc ISEM-MIVEGEC, Montpellier, France) on //in vitro// evolutionary rescue of bacteria stressed by antibiotics and/or bacteriophages targetting //E.coli//. I also participate to the project [[ https://www.chu-lyon.fr/antibioresistance-projet-phag-one|Phag-One]] leaded by Frederic Laurent and Tristan Ferry ([[ https://www.crioac-lyon.fr/phagotherapie-bacteriophage/|Hospice Civile de Lyon]]) on the bacteriophage' host-range targetting //Staphylococcus epidermidis// and //E.coli//. Finally, I'm currently also working on //Salmonella// 'bacteriophages in order to perform long-term efficiency of bacteriophage biocontrol.
+I also work with [[ https://isem-evolution.fr/membre/martin/|Guillaume Martin]] (CNRS, ISEM, Montpellier, France) on //in vitro// evolutionary rescue of bacteria stressed by antibiotics and/or bacteriophages targetting //E.coli//. I also participate to the project [[ https://www.chu-lyon.fr/antibioresistance-projet-phag-one|Phag-One]] leaded by Frederic Laurent and Tristan Ferry ([[ https://www.crioac-lyon.fr/phagotherapie-bacteriophage/|Hospice Civile de Lyon]]) on the bacteriophage' host-range targetting //Staphylococcus epidermidis// and //E.coli//. Finally, I'm currently also working on //Salmonella// 'bacteriophages in order to perform long-term efficiency of bacteriophage biocontrol.
+===== Areas of expertise =====
+  * evolutionary virology
+  * experimental evolution
+  * adaptation
+  * evolution in heterogeneous environment (spatial / temporal heterogeneity)
+  * evolution towards specialisation / generalism
+  * phage therapy and biocontrol
 ====== Collective scientific responsabilities ======
@@ Ligne 40: / Ligne 48: @@
 {{::logo_mivegec.png?100|}}
+  * Head of the group "[[https://mivegec.fr/fr/departements-scientifiques/perturbations-evolution-virulence-pev/equipes-pev|Virostyle]]"
   * Elected representant to the laboratory council of MIVEGEC (Conseil d'unité) 2021-2026
   * Elected representant to the logistic group of MIVEGEC (2018- )
@@ Ligne 48: / Ligne 57: @@
 ====== Present position & education ======
-Main subject of research :
+Main subject of research : “evolution proof” bacteriophage therapy / phage adaptation (host-range and virulence)
-  - “evolution proof” bacteriophage therapy
-  - evaluation of phages participation into bacterial ecosystems present in human genital tract
-Past :
+Past training
   * **Habilitation à diriger les recherches (HDR)**	2017 (“Évolution en environnements variables: pérégrinations scientifiques entre virus de plantes, virus d'insectes, bactéries & bactériophages”. Université de Montpellier. 30 mai 2017)
@@ Ligne 61: / Ligne 68: @@
   * **Post-doctoral position in Hopital Bichat**	2003-2004 (Group « Ecologie et évolution des micro-organismes » in collaboration with O. Tenaillon & E. Denamur, Institut National de la Santé et de la Recherche Médicale (INSERM) Paris, France)
   * **Post-doctoral position in Yale University**	2002-2003 (Paul Turner’ group in Yale University, New-Haven, USA)
-  * **PhD in Biology**	2002 (« Experimental study of the evolution of the mechanism of transmission of the Cauliflower mosaic virus ». Pierre-et-Marie-Curie University, PhD defense on may 6th, 2002.
+  * **PhD in Biology**	2002 (« Experimental study of the evolution of the mechanism of transmission of the //Cauliflower mosaic virus// » ([[https://theses.hal.science/tel-04981558|manuscript pdf here]]). Pierre-et-Marie-Curie University, PhD defense on may 6th, 2002.
   * **DEA  « Biologie, Diversité, adaptation des plantes cultivées »** 	1998 (Institut National d’Agronomie INA-PG – Universités de Paris VI et Paris XI, Ecole Nationale Supérieure Agronomique de Montpellier ENSAM)
   * **Maîtrise (option Evolution & génétique)**	1997 (Université de Montpellier II)
@@ Ligne 72: / Ligne 79: @@
 °  Authors contributed equally to the work
 # corresponding author(s)
+===2024===
+  * Brives C, R. Froissart, B. Perez-Sepulveda & C. Le Marrec. 2024. « [[https://doi.org/10.1089/phage.2023.0047|Thinking Phage Innovations Through Evolution and Ecology]] ». **PHAGE** 5(1)
+  * Maurin A., M. Vasse, C. Breyton, C. Zarate-Chaves, S. Bouzidi, J. Hayer, J. Dainat, Margaux Mesleard-Roux, F-X. Weill, I. G. Bravo, A. Feugier & R. Froissart. 2024. « [[https://doi.org/10.1101/2024.03.13.584857|“This training is bound for glory” : selection by experimental evolution of a bacteriophage with expanded host-range and increased virulence]]. **BioRxiv**
 ===2022===
@@ Ligne 167: / Ligne 178: @@
   - Graduate studies : __Yann Dumont__ (2019-2022, co-suppervision with Pr S. Godreuil, CHU Montpellier), __Anna Happel__ (2017-2020, co-direction with Jo-Ann Passmore, U. Cape-Town), __Sarah François__ (2014-2017, co-suppervision with Dr M. Ogliastro, INRAE), __Juliette Doumayrou__ (2008-2011, co-suppervision with Yannis Michalakis, CNRS)
-====Grant proposal====
+====PhD in progress====
 -2025 : "**Salmonella biocontrol**" -- in charge : Amandine Maurin
 -2025 : "**Study of the antagonistic co-evolution between therapeutic bacteriophages and carbapenem-resistant E. coli**" - in charge Elsa Beurrier
+-2024 : "**étude des savoirs, savoir-faire et enjeux de la domestication de bactériophages à usages thérapeutiques**" - in charge Charlotte Whittington (co-direction avec Charlotte Brives (CNRS, Bordeaux)
 ====== Technical skills ======

Remy Froissart, CNRS

Outils pour utilisateurs

Outils du site

Différences

Outils de la page